Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth

Nature Medicine ◽

10.1038/nm.2018 ◽

2009 ◽

Vol 15 (9) ◽

pp. 1023-1030 ◽

Cited By ~ 219

Author(s):

Romulo J C Albuquerque ◽

Takahiko Hayashi ◽

Won Gil Cho ◽

Mark E Kleinman ◽

Sami Dridi ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Lymphatic Vessel ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endogenous Inhibitor ◽

Vessel Growth ◽

Alternatively Spliced ◽

Endothelial Growth Factor

Download Full-text

Faculty Opinions recommendation of Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1163678.625451 ◽

2009 ◽

Author(s):

David Bates

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Lymphatic Vessel ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endogenous Inhibitor ◽

Vessel Growth ◽

Alternatively Spliced ◽

Endothelial Growth Factor

Download Full-text

Faculty Opinions recommendation of Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1163678.796126 ◽

2009 ◽

Author(s):

Andrius Kazlauskas

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Lymphatic Vessel ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endogenous Inhibitor ◽

Vessel Growth ◽

Alternatively Spliced ◽

Endothelial Growth Factor

Download Full-text

Targeting Lymphatic Vessel Activation and CCL21 Production by Vascular Endothelial Growth Factor Receptor-3 Inhibition Has Novel Immunomodulatory and Antiarteriosclerotic Effects in Cardiac Allografts

Circulation ◽

10.1161/circulationaha.109.910703 ◽

2010 ◽

Vol 121 (12) ◽

pp. 1413-1422 ◽

Cited By ~ 94

Author(s):

Antti I. Nykänen ◽

Henrik Sandelin ◽

Rainer Krebs ◽

Mikko A.I. Keränen ◽

Raimo Tuuminen ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Lymphatic Vessel ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Cardiac Allografts ◽

Endothelial Growth Factor

Download Full-text

Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth.

Proceedings of the National Academy of Sciences ◽

10.1073/pnas.90.19.8915 ◽

1993 ◽

Vol 90 (19) ◽

pp. 8915-8919 ◽

Cited By ~ 307

Author(s):

K. G. Peters ◽

C. De Vries ◽

L. T. Williams

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Blood Vessel ◽

Tissue Repair ◽

Growth Factor Receptor ◽

Receptor Expression ◽

Endothelial Differentiation ◽

Vascular Endothelial ◽

Vessel Growth ◽

Endothelial Growth Factor

Download Full-text

Prognostic Significance Peritumoral Lymphatic Vessel Density and Vascular Endothelial Growth Factor Receptor 3 in Invasive Squamous Cell Cervical Cancer

Translational Oncology ◽

10.1593/tlo.09292 ◽

2010 ◽

Vol 3 (3) ◽

pp. 170-175 ◽

Cited By ~ 21

Author(s):

Shaleen K. Botting ◽

Hala Fouad ◽

Kyler Elwell ◽

Bill A. Rampy ◽

Salama A. Salama ◽

...

Keyword(s):

Cervical Cancer ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Squamous Cell ◽

Lymphatic Vessel ◽

Prognostic Significance ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Lymphatic Vessel Density ◽

Endothelial Growth Factor

Download Full-text

Fortgeschrittenes medulläres Schilddrüsenkarzinom: Vandetanib verbessert das progressionsfreie Überleben

Onkologische Welt ◽

10.1055/s-0038-1631032 ◽

2012 ◽

Vol 03 (02) ◽

pp. 93-92

Author(s):

Alexander Kretzschmar

Keyword(s):

Vascular Endothelial Growth Factor ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Phase Iii ◽

Vascular Endothelial ◽

Medulläres Schilddrüsenkarzinom ◽

Epidermal Growth ◽

Endothelial Growth Factor

Vandetanib ist ein oraler Hemmer des RET-Kinase-, VEGF (Vascular Endothelial Growth Factor Receptor)- und EGFR (Epidermal Growth Factor Receptor)-Signalwegs. In einer zulassungsrelevanten, randomisierten, doppelblinden, placebokontrollierten Phase- III-Studie verlängerte der Tyrosinkinasehemmer das progressionsfreie Überleben (PFS) signifikant länger als Placebo.

Download Full-text

Expression des „Epidermal Growth-Factor Receptor“ (EGFR) und des „Vascular Endothelial Growth Factor“ (VEGF) bei Lymphangioleiomyomatose (LAM)

Pneumologie ◽

10.1055/s-2006-934022 ◽

2006 ◽

Vol 60 (S 1) ◽

Author(s):

H Watz ◽

K Engels ◽

M Amthor ◽

D Kirsten ◽

H Magnussen

Keyword(s):

Vascular Endothelial Growth Factor ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Epidermal Growth ◽

Endothelial Growth Factor

Download Full-text

Faculty Opinions recommendation of Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.11744956.12828054 ◽

2011 ◽

Author(s):

Asma Nusrat

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Receptor Antagonism ◽

Endothelial Growth Factor ◽

Α2β1 Integrin

Download Full-text

Faculty Opinions recommendation of Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.11744956.13740054 ◽

2011 ◽

Author(s):

Richard L Stevens

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Receptor Antagonism ◽

Endothelial Growth Factor ◽

Α2β1 Integrin

Download Full-text

Faculty Opinions recommendation of 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697854.793153053 ◽

2012 ◽

Author(s):

Hendrik van Poppel ◽

Yuri Tolkach

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Renal Cell Cancer ◽

Renal Cell ◽

Cell Cancer ◽

Neoadjuvant Treatment ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endothelial Growth Factor ◽

Receptor Inhibitor

Download Full-text